Several reports confirmed their ability to cross the blood–brain barrier and proved their potency in the treatment of Alzheimer’s disease via interfering with some potential targets, such as AChE and/or ERK2 [12,25]. The gene discussed is MAPK1; the disease is early-onset autosomal dominant Alzheimer disease.